FDA misses approval target dates after plant inspections delayed by COVID travel restrictions
UCB Pharma is informed by agency that action on application for psoriasis treatment is being deferred until on-site visits can be made
The US Food and Drug Administration has told UCB Pharma that it was unable to complete a review of the company’s Biologics License Application for its psoriasis treatment, bimekizumab, by an October 15 deadline due to COVID-19 travel restrictions making on-site manufacturing facility inspections in Europe impossible.
The agency informed UCB via letter and is deferring action on the application for the drug to treat moderate to severe plaque psoriasis until the inspections can be completed.
Under FDA guidance relating to pre-approval inspections during the COVID-19 pandemic, the FDA may defer action on a pending application when a facility inspection is planned but cannot be completed by the Prescription Drug User Fee Action (PDUFA goal) date due to COVID-related travel restrictions, provided that no deficiencies have been identified and the application otherwise satisfies the requirements for approval.
Prof. Dr. Iris Loew Friedrich, Chief Medical Officer and Executive Vice President, Development at UCB said the biopharmaceutical firm was currently in contact with the FDA to schedule inspections of its manufacturing facilities as soon as possible.
“We have provided the Agency with the manufacturing schedules through the first quarter of 2022, and we are eager to assist the FDA to allow its assessment of bimekizumab to be finalized. We are committed to bringing bimekizumab to patients in the US with moderate to severe plaque psoriasis as soon as possible.” she said.
Bimekizumab received marketing authorization in the European Union and Great Britain in August. Regulatory reviews are underway in Australia, Canada, Switzerland and Japan.
The day before, Avadel Pharmaceuticals revealed that the FDA had missed its target action date of October 15, having accepted the NDA for the company’s experimental narcolepsy treatment, FT218.
“We have addressed all questions received to date and remain confident that the package we have submitted satisfies all of the FDA’s requests,” said Greg Divis, CEO of Avadel. “We have not been informed of any deficiencies in our application and remain fully committed to work closely with the FDA for the duration of its review of our NDA for FT218.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance